- Home
- NEUP vs LYRA Comparison
NEUP vs LYRA Comparison
Compare NEUP & LYRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NEUP
- LYRA
- Stock Information
- Founded
- NEUP 1996
- LYRA 2005
- Country
- NEUP United States
- LYRA United States
- Employees
- NEUP N/A
- LYRA N/A
- Industry
- NEUP
- LYRA Medical/Dental Instruments
- Sector
- NEUP
- LYRA Health Care
- Exchange
- NEUP Nasdaq
- LYRA Nasdaq
- Market Cap
- NEUP 12.7M
- LYRA 15.0M
- IPO Year
- NEUP N/A
- LYRA 2020
- Fundamental
- Price
- NEUP $7.01
- LYRA $9.40
- Analyst Decision
- NEUP Strong Buy
- LYRA Buy
- Analyst Count
- NEUP 1
- LYRA 2
- Target Price
- NEUP $21.00
- LYRA $16.00
- AVG Volume (30 Days)
- NEUP 22.3K
- LYRA 1.9M
- Earning Date
- NEUP 08-15-2025
- LYRA 08-13-2025
- Dividend Yield
- NEUP N/A
- LYRA N/A
- EPS Growth
- NEUP N/A
- LYRA N/A
- EPS
- NEUP 0.00
- LYRA N/A
- Revenue
- NEUP $15,662,715.00
- LYRA $1,185,000.00
- Revenue This Year
- NEUP N/A
- LYRA N/A
- Revenue Next Year
- NEUP N/A
- LYRA $1,286.17
- P/E Ratio
- NEUP $4,149.50
- LYRA N/A
- Revenue Growth
- NEUP N/A
- LYRA N/A
- 52 Week Low
- NEUP $2.90
- LYRA $3.81
- 52 Week High
- NEUP $126.00
- LYRA $37.50
- Technical
- Relative Strength Index (RSI)
- NEUP N/A
- LYRA 45.31
- Support Level
- NEUP N/A
- LYRA $10.15
- Resistance Level
- NEUP N/A
- LYRA $14.88
- Average True Range (ATR)
- NEUP 0.00
- LYRA 2.03
- MACD
- NEUP 0.00
- LYRA -0.67
- Stochastic Oscillator
- NEUP 0.00
- LYRA 0.42
About NEUP Neuphoria Therapeutics Inc. Common Stock
Neuphoria Therapeutics Inc is a clinical stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. The company is advancing its drug candidate, BNC 210, an oral, proprietary, selective negative allosteric modulator of the Alpha7 nicotinic acetylcholine receptor, for the acute treatment of social anxiety disorder and for chronic treatment of post-traumatic stress disorder.
About LYRA Lyra Therapeutics Inc.
Lyra Therapeutics Inc is a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients. The Company's operations and manages its business as a single operating segment which is the business of developing targeted medicines to address ears, nose, and throat, or ENT diseases. Its initial product candidates, LYR-210 and LYR-220, are bioabsorbable polymeric matrices designed to be administered in a brief, non-invasive, in-office procedure and intended to deliver continuous drug therapy to the sinonasal passages for the treatment of chronic rhinosinusitis, or CRS.